Kiora and Théa Open Innovation Enter Partnership to Develop and Commercialize KIO-301
Read more
Contact MENU

News

02.05.18

EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery

EGP-437 demonstrated better clinical performance than vehicle control but did not meet its co-primary endpoints WALTHAM, Mass., Feb. 05, 2018 -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a...
Read more
01.04.18

EyeGate Promotes Sarah Romano to Chief Financial Officer

Sarah Romano, elevated from Interim CFO, will lead finance effort during transition to commercialization phase WALTHAM, Mass., Jan. 04, 2018 -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”),...
Read more
12.19.17

EyeGate Awarded New U.S. Patent for Iontophoretic Delivery of Corticosteroids to the Eye

Further Strengthens Global IP Protection for EGP-437 WALTHAM, Mass., Dec. 19, 2017 -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two platform technologies...
Read more
12.18.17

EyeGate Achieves 75% Enrollment in Pivotal Phase 3 Clinical Trial for Anterior Uveitis Triggering Milestone Payment

On track to report topline data in 2Q18 and file NDA within 2018 WALTHAM, Mass., Dec. 18, 2017 -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty...
Read more
11.14.17

EyeGate Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

WALTHAM, Mass., Nov. 14, 2017 -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of...
Read more
11.08.17

EyeGate Completes Enrollment in Phase 2b Clinical Trial of EGP-437 for Cataract Surgery

Triggers Milestone Payment under Global Licensing Agreement with Valeant Pharmaceuticals WALTHAM, Mass., Nov. 08, 2017 -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with...
Read more
11.01.17

EyeGate Appoints Mike Garanzini as Chief Commercial Officer to Develop and Implement Global Launch Strategy

A product marketing veteran with an ophthalmology focus at companies such as Santen, Merck and Pharmacia WALTHAM, Mass., Nov. 01, 2017 -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”),...
Read more
10.23.17

Eye Care Thought Leaders Join EyeGate Scientific Advisory Board

WALTHAM, Mass., Oct. 23, 2017 -- EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company focused on developing and commercializing products using two proprietary platform technologies...
Read more